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Abstract
Inhaled drugs are critical for the treatment of inflammatory airway diseases such
as chronic obstructive pulmonary disease (COPD). To develop better therapeutics
for pulmonary disease it is of potential importance to understand molecular
mechanisms of local biotransformation in the lung. Alveolar epithelial type II
(ATII) cells have a key role in homeostasis in the lung, but little is known about
expression patterns of genes encoding cytochrome P450 (CYP) enzymes in ATII
cells. In addition, alteration of CYP gene expression has not been fully defined in
COPD. We previously established a method to purify ATII cells from the adult
human lung using fluorescence-activated cell sorting. By employing this technique
we determined gene expression patterns of 14 CYP enzymes in ATII cells from
nonsmokers (n = 4) and smokers (n = 4), both having normal pulmonary function.
Although most CYP genes are highly expressed in primary hepatocytes, we found
that CYP1B1 mRNA expression was 7.2-fold higher in ATII compared to hepato-
cytes (P = .0275). Additionally we noted a 3.0-fold upregulation of CYP2C19 and
50% reduction in CYP2J2 mRNA expressions in ATII cells isolated from patients
with COPD (n = 3) compared to smokers without COPD (n = 4). These data, for
the first time, detail a comprehensive set of genes encoding CYP enzymes in
human ATII cells and highlights differentially expressed CYP mRNAs of patients
with COPD. Such understanding may have important implications for the devel-
opment of novel inhaled drugs.
Abbreviations: %FEV1, percent predicted forced expiratory volume in 1 s; ATII cell, an alveolar epithelial type II cell; COPD, chronic obstructive pulmonary disease; CYP, cytochrome P450;
EETs, epoxyeicosatrienoic acids; FACS, fluorescence-activated cell sorting; FEV1, force expiratory volume in 1 s; FOXA3, forkhead box protein A3; FVC, forced vital capacity; PAH, polycyclic
aromatic hydrocarbon; PAHs, polycyclic aromatic hydrocarbons.
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1 | INTRODUCTION
Inhaled drugs such as long-acting beta-agonists, long-acting
antimuscarinic antagonists, and inhaled corticosteroids are used as
therapeutic options for patients with chronic obstructive pulmonary
disease (COPD)1 which is a leading cause of morbidity, mortality,
and health-care costs worldwide.2 In addition to the current treat-
ments, recent advances indicate that next-generation inhaled drugs
including kinase inhibitors have been developed for inflammatory
airway diseases.3 This is because therapeutic agents that are
directly administered to the lungs have at least 2 substantial mer-
its: (i) the rapid onset of action by direct delivery to the airways
and (ii) the local high concentration to minimize the systemic
adverse effects. Susceptibility to drug metabolism in the target
organ has the possibility of reducing effective drug concentration
and producing metabolites that give rise to patient safety risk or
have pharmacological activity. Additionally, a novel candidate drug
may beneficially inhibit an enzyme responsible for producing
potentially toxic metabolites of an inhaled molecule that may be
present in, for example, tobacco smoke. Thus development of
inhaled drugs ideally requires in-depth knowledge of drug biotrans-
formation in the lung.
Expression and functional activity of drug-metabolizing enzymes
including cytochrome P450 (CYP) enzymes can be altered in diseases
of the liver which is the vital organ for metabolisms of orally admin-
istered therapeutics.4 The human pulmonary tissue also expresses a
wide range of CYP enzymes to metabolize a great variety of inhaled
xenobiotics and toxicants, but the expression pattern of lung CYPs
substantially differ from metabolisms in the liver.5–7 A recent study
using a comprehensive expression analysis for genes encoding mem-
brane transporters and phase I and II drug-metabolizing enzymes
indicated that these gene expressions were not significantly altered
in lung tissues from patients with COPD compared to healthy sub-
jects.8 However, given previous reports indicating different expres-
sion patterns of drug-metabolizing enzymes in cell populations such
as alveolar epithelial cells, pulmonary vascular endothelial cells, and
airway macrophages,9,10 cell-type-specific analyses are required to
precisely define differences in CYP gene expression in lung tissues
between healthy subjects and patients with pulmonary diseases. In
the alveolar region alveolar epithelial type I (ATI) and type II (ATII)
cells, together with alveolar macrophages constitute the major cellu-
lar population. While ATI and ATII cells make up approximately 90
and 3% of the alveolar surface area, respectively, ATII cells have
been designated defenders of the alveolus due to their highly differ-
entiated function including role in surfactant synthesis, importance in
the repair process after lung injury.11,12
Among component cells in lung alveolar walls, an alveolar epithe-
lial type II (ATII) cell has a critical role in homeostasis of the alveolar
epithelium which is directly exposed to inhaled xenobiotics or com-
pounds.11,12 Although previous reports using immunohistochemistry
demonstrated the presence of CYP1A1, CYP1B1, and CYP3A5 pro-
teins in ATII cells in human lungs,9,10 no studies have comprehen-
sively clarified expression patterns of CYPs in human ATII cells.
Furthermore, to our knowledge, alteration in the CYP gene expres-
sion in human ATII cells has not been investigated in inflammatory
airway diseases, such as COPD.
In this study, we aimed to determine expression patterns of 14
genes encoding CYP enzymes in human ATII cells using a fluores-
cence-activated cell sorting (FACS)-based method for purifying ATII
cells from human lung tissues.13 In addition, we sought to determine
CYP enzymes that were differentially expressed in ATII cells of
patients with COPD.
2 | MATERIALS AND METHODS
2.1 | Patients and human lung tissue preparation
The Ethics Committees at Tohoku University School of Medicine
and at Japanese Red Cross Ishinomaki Hospital approved this study.
The experiments conformed to the principles set out in the WMA
Declaration of Helsinki. All subjects gave their informed consent.
Patients’ characteristics are shown in Table 1. Human lung tissues
without any pathological abnormalities including tumors, overt
inflammation and fibrosis were obtained from patients who under-
went lung resection for primary lung cancer at the Department of
Thoracic Surgery at Tohoku University Hospital or at Japanese Red
Cross Ishinomaki Hospital. Resected lung tissues were immediately
immersed in a tissue preserve solution (Stem Survive; Kurabo, Osaka,
Japan). We used 1-2 g of lung tissues and isolated cells within 6 h
after surgery.
2.2 | Isolation of alveolar epithelial type II cells
from human lungs
ATII cells were isolated from human lung tissues as previously
described.13 Briefly, single-cell suspensions obtained from lung
tissues were incubated with the following antibodies: Alexa Fluor
700-mouse anti-human CD45 antibody (clone HI30; Biolegend);
phycoerythrin-mouse anti-human EpCAM antibody (clone 1B7; eBio-
science); Alexa Fluor 647-rat anti-human T1a antibody (clone NC-
08; Biolegend); fluorescein isothiocyanate-mouse anti-human VE-
cadherin antibody (clone 55-7H1; BD Pharmingen). 7-amino
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actinomycin D (eBiosciences) was used to eliminate dead cells. A
live/single cell gated CD45-negative/EpCAM-high/T1a-low/VE-cad-
herin-negative cell subset was sorted as an ATII cell population by
FACS Aria II cell Sorter and FACS Diva version 6.1 (BD Biosciences).
This routinely resulted in more than 90% of prosurfactant protein-C-
positive ATII cells. Sorted cells were put into Buffer RLT Plus (Qia-
gen) and stored at 80°C until RNA extraction and quantitative
reverse transcription-polymerase chain reaction (qPCR).
2.3 | Preparation of human hepatocytes
Primary human hepatocytes were obtained from Kaly-Cell (Plob-
sheim, France). Three single donors (67-year-old male, 64-year-old
female and 42-year-old female) were used for experiments. Total
RNA was extracted from freshly thawed cells for a gene expression
analysis.
2.4 | RNA extraction and quantitative reverse
transcription-polymerase chain reaction
Total RNA of human ATII cells and human hepatocytes were isolated
using All Prep Micro Kit (Qiagen). The quantity and quality were
assessed by NanoDrop-2000 (ThermoFisher Scientific). Total RNA
was reverse-transcribed using QuantiTect Reverse Transcription Kit
(Qiagen) according to the manufacturer’s instruction with genomic
DNA elimination. The following Taqman probe sets were used
(Applied Biosystems): CYP1A1, Hs01054797_g1; CYP1A2,
Hs00167927_m1; CYP1B1, Hs02382916_s1; CYP2A6, Hs00868
409_s1; CYP2B6, Hs04183483_g1; CYP2C8, Hs02383390_s1;
CYP2C9, Hs02383631_s1; CYP2C19, Hs00426380_m1; CYP2D6,
Hs00164385_m1; CYP2E1, Hs00559367_m1; CYP2J2, Hs003560
35_m1; CYP2U1, Hs00766273_m1; CYP3A4, Hs00604506_m1;
CYP3A5, Hs04273722_m1; GAPDH, Hs99999905_m1. GAPDH was
used as an endogenous control. Real-time PCR was conducted using
the StepOne Plus Real-Time PCR system (Applied Biosystems)
according to the manufacturer’s instruction. The relative expression
levels of the specific mRNAs were calculated using the DDCt
method.
2.5 | Statistics
All data are presented as the mean  SEM. Statistical analyses were
conducted using GraphPad Prism (GraphPad Software). To compare
2 datasets, 2-tailed unpaired t-test was applied. Correlation was
evaluated by Spearman’s rank-order correlation. P < .05 was consid-
ered significant.
3 | RESULTS AND DISCUSSION
We firstly sought to determine expression patterns of genes encod-
ing 14 CYP enzymes in human ATII cells by comparing to those in
human hepatocytes that are major cell-types metabolizing orally or
systemically administered drugs. We isolated ATII cells from non-
COPD patients (nonsmokers, n = 4; smokers, n = 4) whose tissues
were pathologically confirmed not to have overt inflammation or
fibrotic changes. Among 14 CYP genes tested, CYP1A2 and CYP3A4
mRNAs were not detected in the isolated ATII cells (data not
shown). These 2 enzymes are major CYP isoforms in human liver.14
The data presented here agrees previous studies showing no or very
low expressions of CYP1A2 and CYP3A4 mRNAs in human lung
tissue.8,15
In the remaining 12 CYP genes only CYP1B1 mRNA signifi-
cantly increased in ATII cells compared to hepatocytes (Figure 1).
CYP1B1 metabolically activates polycyclic aromatic hydrocarbons
(PAHs) such as Benzo[a]pyrene contained in tobacco smoke to
ultimately generate mutagenic and carcinogenic compounds.16
Considering recent studies using rat ATII cells indicated that
TABLE 1 Patients’ characteristics
Patient Age Gender Smoking (Pack-years) FEV1/FVC %FEV1 GOLD stage Treatment for COPD Lobe resected
Nonsmoker1 70 F 0 78.0 122.9 N.A. N.A. RU
Nonsmoker2 81 F 0 70.2 98.9 N.A. N.A. LU
Nonsmoker3 78 F 0 78.9 104.2 N.A. N.A. RL
Nonsmoker4 69 F 0 84.0 94.2 N.A. N.A. RL
Smoker1 76 M 61.5 91.8 117.0 N.A. N.A. LL
Smoker2 81 M 60 82.0 92.7 N.A. N.A. LU
Smoker3 44 M 1 83.6 106.5 N.A. N.A. RU
Smoker4 62 M 60 82.0 94.0 N.A. N.A. RU
COPD1 70 M 127.5 51.3 78.0 A LAMA RL
COPD2 79 M 11.5 61.2 77.8 A LABA LU
COPD3 51 M 30 68.1 73.3 A LAMA RU
COPD, chronic obstructive pulmonary disease; FEV1, force expiratory volume in 1 s; FVC, forced vital capacity; %FEV1, percent predicted forced expi-
ratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; LAMA, long-acting muscarinic antagonist; LABA, long-acting
b2 agonist; N.A., not applicable; RU, right upper lobe; LU, left upper lobe; RL right lower lobe; LL, left lower lobe.
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proinflammatory cytokines such as tumor necrosis factor-a aug-
mented genotoxic effects of PAHs through CYP1B1,17,18 our
results give extra weight and importance to the role of such a
mechanism in the development of lung carcinoma under proinflam-
matory conditions.
Although other CYP genes were found to be at approximately
10-fold (3A5, 2J2), 100-fold (2C19, 1A1, 2E1, 2D6) or 1000-fold
(2C8, 2A6, 2B6, 2C9) higher levels in hepatocytes than in ATII cells
(Figure 1), there was only 2-fold difference in the expression level of
CYP2U1 between the 2 cell-types. This is of particular interest since
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F IGURE 1 mRNA expression patterns for 12 CYP enzymes between human primary hepatocytes (Hep, n = 3) and isolated alveolar
epithelial type II cells (ATII, n = 8). n is the number of individuals. Each dot represents an individual and bars indicate the mean  SEM. Two-
tailed unpaired t-test was used for statistics. Open circles, never-smokers; Closed squares, smokers without COPD
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although the expression of CYP2U1 has previously been shown to
be at a lower level in the lung,19 the enzyme is postulated to be
selectively expressed in the brain and thymus of human organs 20
and to metabolize arachidonic acids to ultimately generate 19- or
20-Hydroxyeicosatetraenoic acid.21 Since arachidonic acid-derived
eicosanoids such as prostaglandins and leukotrienes regulate immune
cellular functions in inflammatory airway diseases,22 our data suggest
that additional focus on the role of CYP2U1 in arachidonic acid
metabolism on alveolar epithelium in proinflammatory settings may
be warranted.
A comparison was made for the mRNA expression of the 12
CYP genes in ATII cells from healthy smokers and patients with
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F IGURE 2 Comparison of mRNA
expression of 12 CYP enzymes in ATII cells
between smokers without COPD (n = 4)
and patients with COPD (n = 3). n
indicated the number of individuals. Each
dot represents an individual and bars
indicate the mean  SD. Two-tailed
unpaired t-test was used for statistics
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COPD. Although the sample number was relatively small, CYP2C19
mRNA in ATII cells of COPD patients showed 3.0-fold higher levels
than that in ATII cells from smokers (Figure 2). In contrast, CYP2J2
mRNA in COPD subjects was half the level of that in smokers (Fig-
ure 2). These differences were not identified when whole-lung tis-
sues from smokers and COPD patients were used for analysis.8
CYP2C19 is a major phase 1 enzyme in the liver and is involved
in metabolism of a wide range of drugs such as proton pomp inhibi-
tors and anticancer agents.23 Although genetic polymorphisms are
translated to the poor metabolism of these drugs in some individuals,
recent studies have supported the idea that factors regulating
CYP2C19 transcription are also important for its pharmacokinetics.24
One such transcription factor responsible for transactivation of
CYP2C19 is forkhead box protein A3 or FOXA3.25 The reason for
the higher expression of CYP2C19 in ATII cells from COPD patients
(Figure 2) may be due to the upregulation of FOXA3 in inflamed air-
way epithelium of these patients.26 This data provides a rationale for
the investigation of FOXA3 in the transregulation of CYP2C19 gene
expression in COPD.
CYP2J2 is expressed in extrahepatic tissues, especially in the
heart, but also in the lung19 and is known to metabolize endogenous
arachidonic acids for generating epoxyeicosatrienoic acids (EETs)27
as well as exogenous diverse therapeutics such as antihistamine
drugs.28 Recent studies using mouse models indicate that CYP2J2-
mediated EETs reduce excessive inflammation in the lung and
liver.29,30 Thus the reduced CYP2J2 expression in COPD ATII cells
may contribute to proinflammatory conditions in disease.
In summary, we clarified expression patterns of genes encoding
cytochrome P450 enzymes in alveolar epithelial type II cells (ATII) in
human lung and found higher expression of CYP1B1 mRNA in ATII
cells than in primary hepatocytes. Moreover using the cell-type-spe-
cific approach we for the first time demonstrated that CYP2C19 and
CYP2J2 mRNA expressions were altered in ATII cells in COPD.
These CYP enzymes are known to be able to metabolize kinase inhi-
bitors.31 Taken together with promising roles of kinase inhibitors for
the treatment of COPD,32 our results lead to a new insight into the
altered expression of CYP enzymes in the alveolar epithelium in
inflammatory airway diseases.
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